Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'cheap' on P/E, overvalued on EV/EBITD.
Target Price
The average target price of ALCJ.PA is 4.4 and suggests 100% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc